Key result
Ticagrelor treatment showed no correlation between immature platelet fraction and platelet aggregation (r=0.08), unlike prasugrel (r=0.41; P=0.05 for difference).
Why the study?
Does ticagrelor compared to prasugrel reduce the impact of immature platelets on platelet reactivity in patients with acute coronary syndrome?
Population
124 prospectively enrolled patients with acute coronary syndrome
Comparison
Ticagrelor for P2Y12 receptor inhibition vs Prasugrel for P2Y12 receptor inhibition
Design
RCT, randomly assigned
Authors
Loading...
Reticulated platelets may blunt prasugrel more than ticagrelor response in ACS; leaves open impact on outcomes or drug selection.
RCT (n=124)
Does ticagrelor compared to prasugrel reduce the impact of immature platelets on platelet reactivity in patients with acute coronary syndrome?
Absolute Event Rate: 0.08% vs 0.41%
p-value: p=0.05
Ticagrelor provides more consistent platelet inhibition than prasugrel in the presence of immature (reticulated) platelets in patients with acute coronary syndrome.
Bernlochner et al. (2015) conducted an RCT in Acute coronary syndrome (n=124). Ticagrelor vs. Prasugrel was evaluated on Correlation of platelet aggregation and immature platelet fraction (IPF) (p=0.05). Ticagrelor treatment showed no correlation between immature platelet fraction and platelet aggregation (r=0.08), unlike prasugrel (r=0.41; P=0.05 for difference).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: